Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib
{{output}}
Introduction: Endocrine immune-related adverse events (irAEs) are frequently observed during PD-1/PD-L1 therapy and may indicate active immune engagement during treatment. However, it remains uncertain whether this association pe... ...
